Pelareorep
- Generic Name
- Pelareorep
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1383626-61-6
- Unique Ingredient Identifier
- S9J80L3D1U
- Associated Conditions
- -
- Associated Therapies
- -
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05519059
- Locations
- 🇨🇳
Bethune First Hospital of Jilin University, Chang chun, Jilin, China
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 81
- Registration Number
- NCT01656538
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath